Oncology
Single-stranded oligonucleotides targeting STAT3 destroy prostate cancer
Published in Gene Therapy Weekly, December 30th, 2004
According to recent research from the United States, "signal transducers and activators of transcription (STAT) were originally discovered as components of cytokine signal transduction pathways."
"Persistent activation of one of these transcription factors, STAT3, is a feature of many malignancies, including hormone-resistant prostate cancer. In this regard, malignant cells expressing persistently activated STAT3 become dependent on it for survival, thus rendering STAT3 a potential molecular target for therapy of hormone-resistant prostate cancer," wrote B.E. Barton and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2004-12-30)
More Articles from Gene Therapy Weekly
- Bone Marrow Transplantation
Selective amplifier genes allow gene transduction without marrow conditioning - Gene Promotion
Two-step transcriptional amplification-based vectors ease transgene scrutiny - Nasopharyngeal Cancer
Pro-apoptotic Bims treats and prevents xenografted tumors - Oncology
A new fusion gene construct strengthens the efforts of lymphoma chemotherapy - Antibodies
Companies offer recombinant antibody for detection of cyclophilin A - Apoptosis
p53-dependent replication checkpoint is defective in cancer cells - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
